Abstract 5643
Background
Survival of patients with solid cancer improved over the last decade. Whether this translates in survival advances when they become critically ill is uncertain. We sought to determine trends in survival over time in critically ill patients with solid tumors.
Methods
Retrospective single center cohort of patients with solid tumors admitted to ICU over a 10-year period. Factors independently associated with day-30 and 1-year mortality after ICU discharge were identified.
Results
A total of 669 patients were admitted. Primary site of cancer was lung (21%), digestive (20%) and breast cancer (19%); 335 patients (54%) had metastasis. A decision to withhold/withdraw life sustaining therapies was implemented in 158 (25%) patients. ICU, Day-30 and one-year mortality were 23%, 35% and 41%. Among the 484 (77%) ICU survivors, 248 (39%) actually underwent an oncologic treatment following ICU discharge. Factors associated with day-30 mortality included: the period of ICU admission (HR = 0.7, p = 0.03 after 2010 vs before 2010), poor performance status (>2) (HR = 1.4, p = 0.03), metastatic stage of cancer (vs localized cancer) (HR = 2.1, p = 0.002), need for mechanical ventilation (HR = 4.5, p < 0.0001, or vasopressors (HR = 2.3, p = 0.0003). Decisions for forgo life-sustaining therapy in ICU were also associated with day-30 mortality (HR = 3.3, p < 0.0001). Factors associated with 1-year mortality included ICU admission after 2010 (HR 0.5, p < 0.001), locally advanced (HR = 1.8, p = 0.002) or metastatic cancer (HR = 2.2, p = 0.002), poor performance status (HR = 1.5, p = 0.01), newly diagnosed cancer at ICU admission (HR = 2.0, p = 0.003) the inability to receive a cancer treatment after ICU discharge (HR = 5.3, p < 0.001) and decisions to forgo life-sustaining therapy throughout ICU stay (HR = 2.3, p < 0.001).
Conclusions
In critically-ill oncology patients, survival improves over time. Tumor staging and performance status impact on both short-term and long-term mortality suggesting that the goals of care should be better fine-tuned in the future. Most importantly, patient’s ability to receive cancer treatment and oncologist willingness to provide optimal cancer management are major determinants of 1-year mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
E. Azoulay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract